South San Francisco-based Renovis has inked a deal to collaborate with Pfizer on research into the VR1 receptor that could be worth up to $170 million. Renovis will gain a $10 million licensing fee and $7 million in research money for the next two years. The two companies will focus on developing an inhibitor on VR1, a protein that plays a role in inflicting pain.
- read this article from MSN for more on the deal